Skip to content
ESE logo
European Society of Endocrinology Clinical Practice Guideline: Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition


Eystein S Husebye, Frederik Castinetti, Sherwin Criseno, Giuseppe Curigliano, Brigitte Decallonne, Maria Fleseriu, Claire E Higham, Isabella Lupi, Stavroula A Paschou, Miklos Toth, Monique van der Kooij, Olaf M Dekkers

Developed By:

The European Society of Endocrinology, including representatives from The Endocrine Society and The European Society for Medical Oncology


ICIs have significant endocrine side-effects that physicians treating these patients need to know about, since they are relatively frequent, and their management differs from other immune-related adverse events in three key ways: (i) ICI therapy can be continued in most cases, (ii) high-dose glucocorticoids are rarely required for management, and (iii) endocrine deficiency usually persists, necessitating lifelong replacement, except for cases with transient thyroiditis.

The purpose of this guideline is to provide clinicians with practical guidance on the management of patients with ICI-related endocrine conditions. In clinical practice, both the recommendations and the clinical judgment of the treating physician should be taken into account. Recommendations are not meant to replace clinical acumen and may need adaptation to local circumstances.